Johnson & Johnson JNJ

NYSE · Healthcare · Drug Manufacturers - General

$270.47

Close on Fri, 20 Nov 2026 · market value $651B

What the price is betting on

Below its record

At $270, the price assumes revenue grows about 5.2% a year for five years, from $99.3B to about $123B by FY2030. That is less than what analysts expect for the next two years and about the same as the company's own last three years.

The price assumes5.2%
Analysts, next two years7.3%
Last 3 years5.8%

Revenue growth a year. The price figure comes from a reverse DCF at a 6.5% discount rate.

Track it and Parra checks each report against the path, and tells you when revenue falls behind it.

Own more than JNJ? Check up to 5 of your stocks at once, free, no account.

0$50B$100B$150B$99.3B'23'23'24'25Sep '26'26'27'28'29'30What the price needsReportedAnalysts

Both sides

Three stories, three values

Bear

$259

Base

$308

Bull

$366

Today $270

  • Bear $259. Cash flow grows 4% a year for the next 5 years, slower than expected, then slows to long-run growth.
  • Base $308. Cash flow grows 7% a year for the next 5 years, as analysts expect, then slows to long-run growth.
  • Bull $366. Cash flow grows 10% a year for the next 5 years, faster than expected, then slows to long-run growth.

Stories set by rules from the company’s record.

Checkpoints

The revenue the price needs

  1. YearNeedsAnalysts expect
  2. FY2026$101B$101B, on the path
  3. FY2027$106B$108B, on the path
  4. FY2028$111B$117B, on the path
  5. FY2029$117B$125B, on the path
  6. FY2030$123B$135B, on the path

Each year's revenue at 5.2% growth from $99.3B in the 12 months to September 2026.

At a glance

Healthcare · Drug Manufacturers - General · listed on NYSE

Revenue, FY2025
$94.2B
Growth, 3 years a year
5.8%
Cash margin
21%
Net debt
$27.8B
Shares, 3-year change
−9.1%
Dividend yield
1.9%

What other healthcare prices are betting on

Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.